00:00The lung tumor can unfortunately still be framed as one of the big killers on the national territory.
00:11We still record 44,000 new cases a year and there are some worrying facts.
00:20The first worrying fact is certainly the fact that this tumor still has a close link with cigarette smoke.
00:27The fact that 85% of our patients have been strong smokers
00:33means that if we were magically able to eliminate cigarette smoke,
00:37the lung tumor would suddenly become a rare pathology.
00:41The other worrying fact is the increase among the female population
00:45compared to the male population, which sees a condition of stability in the number of new cases.
00:52The number of new cases among women and the mortality rate is definitely increasing.
00:58And then there are the young people who get sick.
01:01Despite the fact that the average age for the lung tumor continues to be around 69 years old,
01:08there is no doubt that this pathology is increasing even in much younger subjects.
01:13Innovative treatments for the lung tumor are having a significant impact.
01:19They are doing it in terms of quantity of life gained, but above all in terms of quality of life gained.
01:27The introduction of molecular-target drugs and the introduction of immunotherapy
01:33have radically changed our treatment algorithm,
01:38which means that patients who receive these treatments have a discreet quality of life
01:45and have a much longer life expectancy compared to what we could achieve with only chemotherapy.
01:51The development of drugs and the funding of innovative drugs is fundamental,
01:57in the sense that all this innovation does not touch the ground, does not find ground.
02:02If these funds are not allocated, I would say in useful quantities and times, so it is fundamental.
02:11We cannot think that these patients live only thanks to clinical studies,
02:17which is true, they represent a bridge between the unavailability of the drug and its commercial entry.
02:24But then you have to offer the next step.
02:27Until a few years ago, we could not talk about secondary prevention,
02:32that is, we could not talk about screening for the lung tumor,
02:35as is done for other solid tumors, such as the cervical tumor or the breast tumor.
02:40Instead, finally, for about a year and a half, a ministerial network is activated,
02:45which is the RISP network, which sees 18 centers open on the national territory,
02:51in which smokers or ex-smokers aged between 55 and 75 years of age
02:59receive a spiral attack, which is shown to be an examination able to reduce mortality for this pathology,
03:06but they receive it only for a primary prevention.
03:10So, for the first time, secondary prevention and everything that is counseling against smoking
03:16travel together in a prevention program.
Comments